EMA Authorised: Cinacalcet Viatris (previously Cinacalcet Mylan) (cinacalcet hydrochloride) — Mylan Pharmaceuticals Limited

View source ↗

Summary

EMA authorised Cinacalcet Viatris (cinacalcet hydrochloride) for secondary hyperparathyroidism and hypercalcemia, with Mylan Pharmaceuticals Limited as the mark…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypercalcemia
• Hyperparathyroidism

Drugs mentioned

• Cinacalcet Viatris (cinacalcet hydrochloride)

Snippet

Status: Authorised. Therapeutic area: Hyperparathyroidism, Secondary;Hypercalcemia. MAH: Mylan Pharmaceuticals Limited. Decision date: 07/10/2025